WHO forum to accelerate coronavirus research efforts

7 February 2020

superbug_bacteria_virus_antibiotic_amr_big-1

The World Health Organization (WHO) is to convene a global research and innovation forum in an attempt to promote an international response to the coronavirus, 2019-nCoV.

The forum will bring together leading scientists, public health agencies, ministries of health and research funders. Parties involved in public health research and the development of vaccines, therapeutics and diagnostics will attend.

Building on existing SARS and MERS coronavirus research, topics for discussion include identifying the source of the virus as well as sharing of biological samples and genetic sequences.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK